Brokerages Set Annexon, Inc. (NASDAQ:ANNX) Price Target at $12.50

Shares of Annexon, Inc. (NASDAQ:ANNX) have been assigned a consensus recommendation of “Hold” from the five research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $12.50.

Several equities analysts have weighed in on ANNX shares. HC Wainwright reiterated a “buy” rating and issued a $14.00 target price on shares of Annexon in a report on Friday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Annexon in a report on Wednesday, October 8th. Finally, Zacks Research upgraded shares of Annexon from a “strong sell” rating to a “hold” rating in a report on Monday, August 18th.

Annexon Price Performance

NASDAQ:ANNX opened at $3.17 on Tuesday. The firm has a market capitalization of $348.34 million, a price-to-earnings ratio of -2.46 and a beta of 1.36. The company’s 50-day moving average is $2.80 and its two-hundred day moving average is $2.46. Annexon has a 1-year low of $1.28 and a 1-year high of $7.63.

Annexon (NASDAQ:ANNX) last posted its earnings results on Thursday, August 14th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.02. As a group, equities analysts anticipate that Annexon will post -0.96 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Annexon

Several large investors have recently made changes to their positions in ANNX. Sio Capital Management LLC lifted its holdings in shares of Annexon by 20.5% in the 2nd quarter. Sio Capital Management LLC now owns 4,095,764 shares of the company’s stock worth $9,830,000 after acquiring an additional 697,978 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Annexon by 39.9% in the 2nd quarter. Bank of America Corp DE now owns 1,452,795 shares of the company’s stock worth $3,487,000 after acquiring an additional 414,071 shares during the last quarter. Nuveen LLC acquired a new position in shares of Annexon in the 1st quarter worth approximately $670,000. Sirios Capital Management L P lifted its holdings in Annexon by 28.7% during the 2nd quarter. Sirios Capital Management L P now owns 989,577 shares of the company’s stock worth $2,375,000 after buying an additional 220,891 shares in the last quarter. Finally, TFG Asset Management GP Ltd lifted its holdings in Annexon by 6.0% during the 2nd quarter. TFG Asset Management GP Ltd now owns 2,810,000 shares of the company’s stock worth $6,744,000 after buying an additional 160,000 shares in the last quarter.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.